Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03047330 · ClinicalTrials.gov registry record · Phase 4
Menopausal Sleep Fragmentation and Body Fat Gain
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT03047330 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 41 participants.
The verdict
NCT03047330, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study aims to investigate the impact of menopause-related sleep fragmentation on metabolic biomarkers of body fat gain. The investigators hypothesize that experimental sleep fragmentation will result in an adverse leptin response as a metabolic biomarker for body fat gain.
Interventions
- DRUG Estradiol withdrawal
- OTHER Fragmented sleep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2017-07-15 |
| Est. Completion | 2022-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03047330
The ClinicalTrials.gov registry entry for NCT03047330 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Estradiol withdrawal is the first listed.
NCT03047330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03047330 about?
NCT03047330 is a clinical study titled "Menopausal Sleep Fragmentation and Body Fat Gain". This study aims to investigate the impact of menopause-related sleep fragmentation on metabolic biomarkers of body fat gain. The investigators hypothesize that experimental sleep fragmentation will result in an adverse leptin response as a metabolic biomarker for body fat gain.
What is the current status of trial NCT03047330?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2017-07-15. Estimated completion is 2022-08-01.
What interventions are being tested in trial NCT03047330?
The interventions under investigation include: Estradiol withdrawal (DRUG), Fragmented sleep (OTHER).
Who is sponsoring clinical trial NCT03047330?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.